MedPath

Prospective, Monocentric, Interventional Study on Spontaneous Vaginal Clearance of Mycoplasma Genitalium

Not Applicable
Completed
Conditions
Mycoplasma Genitalium Infection
Interventions
Other: Vaginal self-sampling
Registration Number
NCT04841408
Lead Sponsor
University Hospital, Bordeaux
Brief Summary

It is a prospective, monocentric, interventional study on spontaneous vaginal clearance of Mycoplasma genitalium.

The main objective is to evaluate the spontaneous vaginal clearance of M. genitalium in patients coming to perform a voluntary termination of pregnancy at the University Hospital of Bordeaux at 9 weeks after a vaginal sample positive for M. genitalium

Detailed Description

Mycoplasma genitalium is a bacterium that colonizes female genital tract and can be responsible for sexually transmitted infection . M. genitalium can cause cervicitis and more rarely high genital infections.

In the vast majority of cases, presence of M. genitalium is not accompanied by any symptoms and women do not develop disease. Natural history of M. genitalium infection is not well documented. Some studies have shown a natural clearance of infection in women. The published work mainly concerns patients at very high risk of sexually transmitted disease, but we do not have French data.

We propose to study the natural clearance of M. genitalium infection in patients consulting at the Orthogeny Centre of the University Hospital of Bordeaux. Results of this work will allow us to have a better knowledge of the natural history of M. genitalium infection.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
69
Inclusion Criteria
  • Patient selected during the first consultation, pre-abortion, and having a vaginal swab positive to M. genitalium.
  • Patient hospitalized for an abortion at the University Hospital of Bordeaux.
  • An affiliated patient or beneficiary of a social security system.
  • Signing free and informed consent.

Exclusion criteria:

  • Patient with vaginal co-infection with C. trachomatis.
  • Patient with symptoms of high genital infection.
  • Taking fluoroquinolones, macrolides or tetracyclines within 21 days of inclusion.
  • Patient under legal protection.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Vaginal self-samplingVaginal self-samplingVaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
Primary Outcome Measures
NameTimeMethod
clearance at week 3Week 3

The clearance will be defined by a negative PCR test for M. genitalium in the vaginal sample taken at week 3.

Secondary Outcome Measures
NameTimeMethod
Prevalence of M. genitalium infectionsWeek 3, Week 9

Prevalence of infections with M. genitalium, calculated by making the ratio between the number of patients with a positive vaginal swab for M. genitalium compared to the total number of patients tested.

Prevalence of N. gonorrhoeae infectionsWeek 3, Week 9

Prevalence of infections with N. gonorrhoeae calculated by making the ratio between the number of patients with a positive vaginal swab for N. gonorrhoeae compared to the total number of patients tested.

Prevalence of C. trachomatis infectionsWeek 3, Week 9

Prevalence of infections with C. trachomatis calculated by making the ratio between the number of patients with a positive vaginal swab for C. trachomatis compared to the total number of patients tested.

clearance at week 9Week 9

The clearance defined by a negative PCR test for M. genitalium in the vaginal sample taken at week 9.

patient's sex lifeWeek 3, Week 9

patient's sex life, assessed by a self-questionnaire

Trial Locations

Locations (1)

CHU Bordeaux

🇫🇷

Bordeaux, France

© Copyright 2025. All Rights Reserved by MedPath